Apr 20 |
Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the brunt
|
Mar 1 |
Repare Therapeutics Full Year 2023 Earnings: Misses Expectations
|
Feb 28 |
Repare Therapeutics GAAP EPS of -$0.67 misses by $0.34, revenue of $13.05M misses by $5.88M
|
Feb 28 |
Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023
|
Feb 28 |
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Feb 20 |
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
|
Feb 17 |
We're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Rate
|
Feb 15 |
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
|
Feb 13 |
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
|
Feb 13 |
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
|